Verana Health, a digital health company elevating quality in real-world data (RWD) and Sight Sciences, an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced a research collaboration designed to provide insights that may lead to improved outcomes for patients with primary open-angle glaucoma (POAG).
Sight Sciences will leverage Verana Health's Qdata Glaucoma RWD module to evaluate various facets of its OMNI Surgical System — a minimally invasive, implant-free glaucoma procedure that uniquely addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm's canal and the collector channels.
Intraocular Pressure (IOP) is the only known modifiable risk factor for glaucoma, and OMNI enables surgeons to reduce IOP while avoiding more aggressive surgical interventions or foreign body implants associated with legacy minimally invasive glaucoma surgery (MIGS) procedures.
Powered by real-world glaucoma data curated from the American Academy of Ophthalmology (Academy) IRIS Registry (Intelligent Research in Sight), Qdata Glaucoma is the only data module that captures the full, real-world glaucoma patient journey. This fit-for-purpose data module offers curated data for:
More than 5 million de-identified patients with linked closed claims
More than 341,000 glaucoma patients who received MIGS procedures
MIGS procedure details and IOP readings
An average of 2.9 years follow-up for glaucoma patients
Join the HealthXL Webinar on ‘Retail Healthcare: Current and Future Opportunities for Digital Health’ on 26th January. Click here to Request to Join.
Click here to read the original news story.